Absci (ABSI) investor relations material

Company overview and technology

• Focuses on AI-driven drug discovery, particularly targeting the prolactin receptor for multiple indications.

• Early adoption of AI enables design of antibodies and drugs with desired attributes, moving beyond traditional trial-and-error methods.

• Two clinical programs target androgenic alopecia (AGA) and endometriosis, leveraging unique biology of the prolactin receptor.

• Proprietary multimodal AI platform integrates data generation, validation, and agentic workflows for rapid cycle times.

• Partnerships have demonstrated ability to drug challenging targets, such as ion channels, with high specificity.

Clinical pipeline and development plans

• Lead asset ABS-201 is advancing in AGA, with top-line safety and PK data expected in the first half of the year and 13-week interim efficacy data in the second half.

• Full 26-week study aims for 30–40 hairs/cm² increase, with 13-week data seen as directional.

• Endometriosis program to initiate phase II in Q4, targeting pain reduction and disease modification.

• Registrational studies for AGA expected to require ~1,500 patients, with rapid recruitment and lower costs anticipated.

• Cash runway extends into the first half of 2028, supporting key readouts for both AGA and endometriosis.

Market opportunity and commercialization strategy

• AGA market estimated at over $25 billion, with potential to treat 5–9 million patients annually in the U.S.

• Consumer research indicates strong dissatisfaction with current treatments and high interest in ABS-201's profile (few injections, long durability).

• Plans for a hybrid go-to-market strategy: initial focus on dermatologists, followed by direct-to-consumer channels leveraging social media and brand-building.

• Strategy modeled after successful brands like BOTOX, aiming for sustained market share post-patent expiry.

• Potential for combination therapies with existing treatments like minoxidil, offering additive benefits.